Hypertension study in anaesthetized rabbits: protocol proposal for AT 1 antagonists screening

Abstract

Introduction: The aim of this study was to establish an optimized fast and safe protocol for the pharmacological screening of AT₁ antagonists.

Materials and methods : The pharmaceutical prototype AT₁ antagonist losartan, its active metabolite EXP3174 and the synthetic compound MMK1 were analysed in order to validate the protocol. Ang II was continuously infused while the animals received the drugs in two procedures.

Results: In the post-treatment procedure drugs were administered either in a single bolus dose or in a sequential manner. When losartan was administered in a single bolus dose, efficacy was evident until the 7th min (p=0.012) whilst EXP3174 infusion extended the efficiency up to the end of the study (p=0.006). In addition, the sequential injections of losartan prolonged the inhibitory time interval until the end of the study (p=0.045). In the pre-treatment procedure, results suggested a dose-dependent inhibitory effect for both antagonists. The pressor response to Ang II was unchanged after MMK1 administration either in the post- or in the pre-treatment mode.

Conclusions: The proposed protocol appears to be safe, simple and fast for the pharmacological screening of AT₁ antagonists and enables the evaluation of new antagonists using lower doses than any other reported in the literature.

Keywords

animal model AT1 antagonist EXP3174 hypertension losartan

Get full access to this article

View all access options for this article.

References

Schmidt B. and Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites . J Med Chem 2003; 46: 2261-2268.

Menard J. , Bouhnik J. , Clauser E. , Richoux JP and Corval O. Biochemistry and regulation of angiotensinogen. Clin Exp Hypertens A 1983; 5: 1005-1019.

Scheuer DA and Perrone MH Angiotensin type 2 receptors mediate depressor phase of biphasic pressure response to angiotensin. Am J Physiol 1993 ; 264: R917-R923.

Cowley AW and Bobert EM Acute and chronic dose-response relationships for angiotensin, aldosterone, and arterial pressure at varying levels of sodium intake. Circ Res 1976; 39: 788-797.

Rowe BP and Nasjletti A. Biphasic blood pressure response to angiotensin II in the conscious rabbit: Relating to prostaglandins. J Pharmacol Exp Ther 1983; 225: 559-563.

Morton JJ The renin-angiotensin system. In: Robertson JIS and Nicholls GM (eds), Biochemistry, Physiology, Pathophysiology and Therapeutics. New York : Gower Medical Publishing/ Raven Press, 1993; pp. 9.1-9.12.

Carini DJ , Duncia JV , Johnson AL , Chiu AT , Price WA , Wong PC , Timmermans PB Nonpeptide angiotensin II receptor antagonists: N-[(benzyloxy)benzyl]imidazoles and related compounds as potent antihypertensives. J Med. Chem 1990; 33: 1330-1336.

Duncia JV , Carini DJ , Chiu AT , Johnson AL , Price WA , Wong PC , et al. The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med Res Rev 1992; 12: 149-191.

Duncia JV , Chiu AT , Carini DJ , Gregory GB , Johnson AL , Price WA , et al. The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J Med Chem 1990; 33: 1312-1329.

10.

Wu W. , Zhang Y. , Ballew JR , Fink G. and Wang DH Development of hypertension induced by subpressor infusion of Angiotensin II. Hypertension 2000; 36: 549-552.

11.

Lilach LO , Alejandro RC , Vincenzo S. , Claudio N. Animal models of hypertension: An overview. J Lab Clin Med 2005; 146: 160-173.

12.

Wong PC , Price WA Jr , Chiu AT , Carini DJ , Duncia JV , Johnson AL , et al. Nonpeptide angiotensin II receptor antagonists: Studies with EXP 9270 and DuP 753. Hypertension 1990; 15: 823-834.

13.

Wong PC , Price WA Jr , Chiu AT , Duncia JV , Carini DJ , Wexler RR , et al. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 719-725.

14.

Gorbea-Oppliger VJ , Melaragno MG , Potter GS , Pettit RL and Fink GD Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects. J Pharmacol Exp Ther 1994; 271: 804-810.

15.

Osei SY , Minkes RK , Bellan JA and Kadowitz PJ Analysis of the inhibitory effects of DuP 753 and EXP 3174 on responses to angiotensin II in the feline hindquarters vascular bed. J Pharmacol Exp Ther 1993; 264: 1104-1112.

16.

Yun CH , Lee H. , Rho JK , Jeong HG and Guengerich FP Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P450 3A (4) in formation of the active metabolite EXP 3174. Drug Metab Dispos 1995; 23: 285-289.

17.

Wong PC , Price WA Jr , Chiu AT , Duncia JV , Carini DJ , Wexler RR , et al. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP 3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255: 211-217.

18.

Goldblatt H. , Lynch J. , Hanzal RF and Summerville WW Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934; 59: 347-379.

19.

Pinto YM , Paul M. and Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering . Cardiovasc Res 1998; 39: 77-88.

20.

Bruna RD , Bernhard I. , Gess B. , Schricker K. and Kurtz A. Renin gene and angiotensin II AT1 receptor gene expression in the kidneys of normal and of two-kidney/one-clip rats. Pflugers Arch 1995; 430: 265-272.

21.

Panek RL , Ryan MJ , Weishaar RE and Taylor DG Development of a high renin model of hypertension in the cynomolgus monkey . Clin Exp Hypertens A 1991; 13: 1395-1414.

22.

Wiesel P. , Mazzolai L. , Nussberger J. and Pedrazzini T. Two-kidney, one clip and one- kidney, one clip hypertension in mice. Hypertension 1997; 29: 1025-1030.

23.

Anderson WP , Ramsey DE and Takata M. Development of hypertension from unilateral renal artery stenosis in conscious dogs. Hypertension 1990; 16: 441-451.

24.

Xie P. , Chapleau M. , McDowell TS , Hajduczok G. and Abboud FM Mechanism of decrease baroreceptor activity in chronic hypertensive rats. J Clin Invest 1990; 86: 625-630.

25.

Fitts DA , Zierath DK , Savos AV , Ho JM and Barsett JE Intravenous angiotensin and salt appetite in rats. Appetite 2007; 48: 69-77.

26.

Correia AG , Bergstrom G. , Jia J. , Anderson WP and Evans RG Dominance of pressure natriuresis in acute depressor responses to increased renal artery pressure in rabbits and rats. J Physiol 2002; 538: 901-910.

27.

Denton KM , Lamden M. , Shweta A. , Alcorn D. and Anderson WP Chronic angiotensin converting enzyme inhibition enhances renal vascular responsiveness to acetylcholine in anaesthetized rabbits. J Hypertens 2001; 19: 1497-1503.

28.

Moutevelis-Minakakis P. , Gianni M. , Stougiannou H. , Zoumpoulakis P. , Zoga A. , Vlahakos AD , et al. Design and synthesis of novel antihypertensive drugs. Bioorg Med Chem Lett 2003; 13: 1737-1740.

29.

Mavromoustakos T. , Moutevelis-Minakakis P. , Kokotos CG , Kontogianni P. , Politi A. , Zoumpoulakis P. , et al. Synthesis, binding studies and in vivo biological evaluation of novel non-peptide antihypertensive analogues. Bioorg Med Chem 2006; 14: 4353-4360.

30.

Rowe BP and Dixon B. Angiotensin III depressor action in the conscious rabbit is blocked by losartan but not PD 123319. Hypertension 2000; 35: 130-134.

31.

Gavras H. , Kremer D. , Brown JJ , Gray B. , Lever AF , MacAdam RF , et al. Angiotensin-and norepi-nephridineinduced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J 1975; 89: 321-332.

32.

Vlahakos DV , Matsoukas IM , Ancans J. , Moore G. , Iliodromitis E. , Marathias K. Biological activity of the novel cyclic angiotensin II analogue [Sar1,Lys3,Glu5]ANG II. LIPS 1996 ; 4: 191-194.

33.

Nielsen LB , Stender S. , Kjeldsen K. and Nordestgaard BG Effect of angiotensin II and enalapril on transfer of low-density lipoprotein into aortic intima in rabbits. Circ Res 1994 ; 75: 63-69.

34.

Zoumpoulakis P. , Zoga A. , Roumelioti P. , Giatas N. , Grdadolnik SG , Iliodromitis E. , et al. Conformational and biological studies for a pair of novel synthetic AT1 antagonists: stereoelectronic requirements for antihypertensive efficacy. J Pharm Biomed Anal 2003; 31: 833-844.

35.

Yamamoto T. , Wang L. , Shimakura K. , Sanaka M. , Koike Y. and Mineshita S. Angiotensin II-induced pulmonary edema in a rabbit model. Jpn J Pharmacol 1997; 73: 33-40.